Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb 10:284:114797.
doi: 10.1016/j.jep.2021.114797. Epub 2021 Nov 1.

Artemisia annua L. hot-water extracts show potent activity in vitro against Covid-19 variants including delta

Affiliations
Free PMC article

Artemisia annua L. hot-water extracts show potent activity in vitro against Covid-19 variants including delta

M S Nair et al. J Ethnopharmacol. .
Free PMC article

Abstract

Ethnopharmacological relevance: For millennia, Artemisia annua L. was used in Southeast Asia to treat "fever". This medicinal plant is effective against multiple pathogens and is used by many global communities as a source of artemisinin derivatives that are first-line drugs to treat malaria caused by Plasmodium parasites.

Aim of the study: The SARS-CoV-2 (Covid-19) global pandemic has killed millions and evolved numerous variants, with delta being the most transmissible to date and causing break-through infections of vaccinated individuals. We further queried the efficacy of A. annua cultivars against new variants.

Materials and methods: Using Vero E6 cells, we measured anti-SARS-CoV-2 activity of dried-leaf hot-water A. annua L. extracts of four cultivars, A3, BUR, MED, and SAM, to determine their efficacy against five infectious variants of the virus: alpha (B.1.1.7), beta (B.1.351), gamma (P.1), delta (B.1.617.2), and kappa (B.1.617.1).

Results: In addition to being effective against the original wild type (WT) WA1, A. annua cultivars A3, BUR, MED, and SAM were also potent against all five variants. IC50 and IC90 values based on measured artemisinin content ranged from 0.3 to 8.4 μM and 1.4-25.0 μM, respectively. The IC50 and IC90 values based on dried leaf weight (DW) used to make the tea infusions ranged from 11.0 to 67.7 μg DW and 59.5-160.6 μg DW, respectively. Cell toxicity was insignificant at a leaf dry weight of ≤50 μg in the extract of any cultivar.

Conclusions: Results suggest that oral consumption of A. annua hot-water extracts (tea infusions) could potentially provide a cost-effective therapy to help stave off the rapid global spread of these variants, buying time for broader implementation of vaccines.

Keywords: Artemisinin; Covid-19; Delta variant; Gamma variant; Kappa variant; SARS-CoV-2.

PubMed Disclaimer

Figures

Image 1
Graphical abstract
Fig. 1
Fig. 1
SARS-CoV-2 variant inhibition by four cultivars of A. annua L. hot water extracts normalized to their artemisinin content and compared to WT. WT, USA/WA1; variants: B.1.1.7, alpha; B.1.351, beta; P.1, gamma; B.1.617.1, kappa; B.1.617.2 delta) at a multiplicity of infection (MOI) of 0.1 in Vero E6 cells. Data for alpha and beta variants are extrapolated from Nair et al. (2021). Data are plotted from an average of three replicates ± SE.

Similar articles

Cited by

References

    1. Cao R., Hu H., Li Y., Wang X., Xu M., Liu J., Zhang H., Yan Y., Zhao L., Li W. Anti-SARS-CoV-2 potential of artemisinins in vitro. ACS Infect. Dis. 2020;6:2524–2531. - PubMed
    1. Dinnon K.H., Leist S.R., Schäfer A., Edwards C.E., Martinez D.R., Montgomery S.A., West A., Yount B.L., Hou Y.J., Adams L.E. A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures. Nature. 2020;586:560–566. - PMC - PubMed
    1. Ferreira J.F., Luthria D.L., Sasaki T., Heyerick A. Flavonoids from Artemisia annua L. as antioxidants and their potential synergism with artemisinin against malaria and cancer. Molecules. 2010;15:3135–3170. - PMC - PubMed
    1. Gendrot M., Andreani J., Boxberger M., Jardot P., Fonta I., Le Bideau M., Duflot I., Mosnier J., Rolland C., Bogreau H. Antimalarial drugs inhibit the replication of SARS-CoV-2: an in vitro evaluation. Trav. Med. Infect. Dis. 2020;37:101873. - PMC - PubMed
    1. Gendrot M., Duflot I., Boxberger M., Delandre O., Jardot P., Le Bideau M., Andreani J., Fonta I., Mosnier J., Rolland C. Antimalarial artemisinin-based combination therapies (ACT) and COVID-19 in Africa: in vitro inhibition of SARS-CoV-2 replication by mefloquine-artesunate. Int. J. Infect. Dis. 2020;99:437–440. - PMC - PubMed

Supplementary concepts